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LETTER TO THE EDITOR
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Ahmed Dahmani5, Elodie Montaudon5, Cécile Reyes5, David Gentien5, Fabien Reyal7,8, Francesco Ricci4, 
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Abstract 
Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant 
metastatic potential. Chemotherapy has been used in the management of advanced AME patients, however the 
majority of treatments are not effective. Recent studies report recurrent mutations in the HRAS Q61 hotspot in small 
series of AMEs, but there are no preclinical or clinical data showing H‑Ras protein as a potential therapeutic target in 
malignant AMEs. We performed targeted sequencing of tumours’ samples from new series of 13 AMEs, including 9 
benign and 4 malignant forms. Samples from the breast tumour and the matched axillary metastasis of one malig‑
nant HRAS mutated AME were engrafted and two patient‑derived xenografts (PDX) were established that reproduced 
the typical AME morphology. The metastasis‑derived PDX was treated in vivo by different chemotherapies and a com‑
bination of MEK and BRAF inhibitors (trametinib and dabrafenib). All malignant AMEs presented a recurrent mutation 
in the HRAS G13R or G12S hotspot. Mutation of PIK3CA were found in both benign and malignant AMEs, while AKT1 
mutations were restricted to benign AMEs. Treatment of the PDX by the MEK inhibitor trametinib, resulted in a marked 
anti‑tumor activity, in contrast to the BRAF inhibitor and the different chemotherapies that were ineffective. Overall, 
these findings further expand on the genetic features of AMEs and suggest that patients carrying advanced HRAS‑
mutated AMEs could potentially be treated with MEK inhibitors.
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To the Editor,
Adenomyoepithelioma (AME) of the breast is a rare 
biphasic tumour of breast composed of epithelial and 
myoepithelial cells. It is generally a benign disease and 
cases of malignant AME are rare [1]. Importantly, how-
ever, metastases have been documented even in cases 
lacking a histologically overt malignant component [2]. 
The epithelial component may express estrogen receptor 
(ER) and progesterone receptor (PR) [1]. Given the rarity 
of the disease, most of the literature consists of individ-
ual case reports or studies with a few patients. A specific 
treatment for metastatic AME has not been determined, 
and the prognosis of malignant AME with distant metas-
tases is very poor [3, 4].
In the present study we analyzed the mutational pro-
file of 13 AMEs (9 benign and 4 malignant forms), whose 
histo-pathological characteristics are summarized in 
Table 1. These cases were diagnosed as AMEs based on 
the criteria defined by 2019 World Health Organization 
Classification of the Breast Tumours [5]. Nine AMEs 
(69%) expressed estrogen receptor (ER). The mutational 
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analysis revealed recurrently mutated genes, includ-
ing HRAS (5/13, 38%), PIK3CA (4/13, 31%), and AKT1 
(4/13, 31%) (Table 1). The HRAS mutations affected the 
following mutation hotspots: three p.G13R, one p.G12S 
and one p.Q61R hotspot mutations. Mutations in the 
AKT1 gene (E17K) were exclusively found in benign 
ER + AMEs, while three out of four PIK3CA mutations 
(H1047R) were detected in ER-negative AMEs. HRAS 
was mutated in the four malignant AMEs (three in the 
G13R and one in the G12S hotspots), suggesting that 
these mutation hotspots may represent important driver 
of malignant AMEs. To our knowledge, only one case of 
malignant AME mutated for the HRAS G12 hotspot was 
previously identified (G12D) [6]. The low frequency of 
HRAS Q61R/K mutation hotpsot was in agreement with 
two studies [6, 7], while a third study published by Geyer 
et  al. reported recurrent mutations of the HRAS Q61R 
mutation [8].
Mutations in the AKT1 and PIK3CA genes were mutual 
exclusive in our series, while 2 out of four malignant 
AMEs harboured mutations in both HRAS and PIK3CA 
genes. These findings are concordant with those previ-
ously reported [7, 8] and underline the co-occurrence of 




Fig. 1 Treatment response of a PDX established from a AME patient (T13). a Clinical history of patient T13 and PDX establishment from the breast 
and the axillary lymph node tumour samples. The patient presented a mammary breast lesion initially diagnosed as atypical papilloma. The patient 
relapsed and underwent partial mastectomy 18 months later. The breast lesion was a benign AME, characterized by a proliferation of myoepithelial 
cells p63+, CD10+ around epithelium‑lined spaces in a lobulated, tubular and papillary pattern. This lesion was sequenced and the HRAS G12S 
mutation was identified. Six months later, the patient presented a growing breast nodule in the same area and an axillary lymph node and bilateral 
lung metastases. Core needle biopsy of the breast tumour revealed a malignant AME ER positive. A biopsy of a lung metastasis was sequenced 
and the HRAS G12S mutation was identified. The patient received 6 cycles of chemotherapy with paclitaxel and bevacizumab followed by AC 
(Adriamycin + Cyclophosphamide). Repeat CT scans of the thorax showed progression of the lung metastases during and after chemotherapy 
treatment. Total mastectomy with axillary lymph node dissection after 12 months of chemotherapy was performed. The breast primary tumour 
was multifocal and 25% of cancer cells were ER positive. One lymph node (LN) was metastatic with capsular effraction. Samples from the breast 
tumor and the LN metastasis carried the HRAS G12S mutation and were engrafted to generate HBCx‑120 and HBCx‑121 PDX models, respectively. 
b histology of patients’ breast tumour and lymph node metastasis and matched PDX HBCx‑120 and HBCx‑121. Scale is indicated by a black bar 
measuring 100 µm (first row) and 50 µm (second and third rows). The breast tumour and the matched PDX HBCx‑120 were ER + (25%) and PR 
negative. c Tumour growth of HBCx‑121 PDX in response to different chemotherapies (eribulin, AC and capecitabine) and to the combination of 
trametinib with. Statistical analysis of tumour growth inhibition based on relative tumour volume was performed with the Mann–Whitney test. d 
Western Blot analysis of treated tumours showing the phosphorylation status of AKT, MEK, p44/42 MAPK (ERK) and S6. Tumours were harvested 
after 3 weeks of treatment and three xenografts from each treatment group were analysed
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From one of the four malignant AMEs patients (T13), 
whose clinical history is summarized in Fig. 1a, we could 
generate two PDX, HBCx-120 and HBCx-121, estab-
lished from the engraftment of the breast tumour and 
the axillary lymph node metastasis, respectively. The 
histological analysis of xenografts tumors showed that 
tumor morphology and immunohistochemistry profile 
was concordant with patient’s samples (Fig.  1b). Both 
patient’s nodal metastasis and HBCx-121 PDX show loss 
of ER expression, as compared to the matched breast 
tumour and HBCx-120 PDX. This phenotypic discord-
ance between the primary tumor and the metastasis is 
frequent in breast cancer progression and metastases, 
is generally associated to a worse survival and could be 
a consequence of intra-tumour heterogeneity and sub-
clonal evolution of ER negative cells in the nodal metas-
tasis [9, 10].
Patient’s tumour samples including the two mas-
tectomies (partial and total), the lymph node and the 
lung metastasis, and PDX samples carried the HRAS 
p.Gly12Ser mutation hotspot. As HRAS mutations are 
associated to activation of RAF/MEK/ERK signaling 
in different cancers [11], we treated the PDX HBCx-
121 by a combination of dabrafenib (a RAF inhibitor) 
and trametinib (a MEK1/2 inhibitor). In parallel, we 
determined the response to different chemotherapies: 
AC (Adriamycin and cyclophosphamide), capecitabine 
and eribulin, three standard of care currently used for 
breast cancer treatment. PDX HBCx-121 responded 
with stable disease to trametinib (tumour growth inhi-
bition of 82%), while dabrafenib had no effect on tumor 
growth (Fig.  1c). The combination of trametinib with 
dabrafenib did not increase the anti-tumour activity, 
suggesting that the combination effects are mediated by 
the MEK inhibitor. The PDX was resistant to the three 
chemotherapies tested.
To our knowledge, there are no clinical nor preclini-
cal evidence showing that patients or PDX models of 
HRAS mutated AMEs could respond to MEK inhibitors. 
Trametinib as a single-agent is approved for the treat-
ment for metastatic melanoma in patients with BRAF 
V600E or V600K mutations [12]. Inhibition of MAPK 
and P-AKT signaling pathways in treated tumours was 
analysed by Western Blot (Fig.  1d). Phospho-p44/42 
MAPK (Erk1/2) was strongly inhibited in the combi-
nation group, while in trametinib-treated tumours the 
inhibition was heterogeneous among the different xen-
ografts. In tumours treated by the combination, expres-
sion of P-AKT was strongly inhibited and expression of 
P-S6, the downstream effector of the PI3K/AKT/mTOR 
pathway, was decreased. This indicates that targeting 
the MAPK pathway with inhibitors that act at differ-
ent levels, leads to a more profound inhibition of both 
P-ERK and P-AKT pathways, although this was not 
associated to increased anti-tumour activity.
In summary, we report a new series of AMEs show-
ing recurrent mutations in the HRAS G12 and G13 
hotspots. The treatment of a HRAS-mutated AME 
PDX with a FDA-approved MEK inhibitor (trametinib) 
exhibited significant anti-tumour activity, demon-
strating that HRAS mutation is a therapeutic target in 
malignant AMEs. MEK inhibitors could be an impor-
tant new approach for the treatment of HRAS mutated 
AMEs patients.
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